| | Decoding the Future: Quantum, AI, and Innovation Take Center Stage at BHCR Week 2025 | |
The 11th Annual BioHealth Capital Region Week from September 23rd through the 25th, brought together leaders from across the life sciences, government, and academia to explore the convergence of technology and human ingenuity shaping the next generation of healthcare innovation. From discussions on artificial intelligence in drug development to the promise of quantum computing in medical discovery, this year’s theme “Where Human and Artificial Intelligence Converge in the BioHealth Industry”, were discussed across panels, keynotes, and networking sessions.
Keynote speakers William “Whurley” Hurley, Founder and CEO of Strangeworks, and Matthew Keesan, Vice President and General Manager of Quantum Platform at IonQ, delivered keynotes.
| | Startups, Science, and Standout Pitches Define the 2025 Crab Trap | |
The 2025 Crab Trap Competition once again showcased the incredible entrepreneurial talent within the BioHealth Capital Region and beyond. This year’s winning company, Perfusion Medical of Reston, Virginia, impressed judges with its breakthrough therapy designed to restore blood flow and oxygen delivery after trauma or ischemic injury. The company received a $10,000 cash award from BHI and $25,000 in IT services from InfoPathways.
Chariot Biosciences of Baltimore, Maryland, was recognized for its innovative biologic delivery platform, earning $10,000 in CRO services provided by Accelevir and Noble Life Sciences. With over 60 applications received, the Crab Trap continues to celebrate innovation and opportunity, cementing its role as a launchpad for the next generation of biohealth breakthroughs.
| |  | MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | |
ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company based in Seattle, Washington.
Moonlight Bio will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its T cell therapy pipeline.
| | | Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases | GERMANTOWN, Md. and ALTRINCHAM, United Kingdom, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immunology and inflammation company focused on developing therapies that promote immune tolerance, and Clywedog Therapeutics, Inc. (“Clywedog”), a private company advancing novel breakthrough medicines in diabetes, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. The newly combined company will advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases... | | | Maryland Stem Cell Research Fund Awards $4.7 million to Support Innovations in Stem Cell Research | |
COLUMBIA, Md., (October 2, 2025) – The Maryland Stem Cell Research Commission (the Commission) awarded $4,707,142 in grant funding to accelerate the development of innovative stem cell–based therapies. The Maryland Stem Cell Research Fund (MSCRF), overseen by the Commission, is an independent program within TEDCO designed to promote human stem cell research and treatments through grants to entities in Maryland.
The first round of funding for fiscal year 2026 will support 11 projects targeting a wide range of conditions including neurodegenerative...
| | | Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results | |
ROCKVILLE, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic, platelet-derived, cellular therapeutics, today announced that it has received the final topline results from its CRYPTICS clinical study and is pleased to report that it met the study’s primary efficacy endpoint.
To address a US public health crisis caused...
| | | Novavax Announces Progress on Sanofi Agreement | GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant. The companies have amended their CLA to expand Sanofi's license to include use of Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. Sanofi recently received funding from the Biomedical Advanced Researc... | | | Rockville's OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates | |
ROCKVILLE, Md., Oct. 02, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company’s co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital.
OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs...
| | | GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award | GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, alongside Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina, today announced the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation’s first multi-state genomic newborn screening initiative. | | | Indo US Bridging RARE Summit 2025 | |
Nov 2 - 4 at George Mason University in Virginia, and Organized in collaboration with George Mason University the Bridging Rare Summit 2025 will feature an exciting lineup of prominent speakers from India and the US, workshops, and a Gala dinner and Award Ceremony.
Join the Indo US Bridging RARE Summit 2025 — where global experts unite to advance patient-focused rare disease research.
Early Bird Registration closing soon! Use code EARLYBIRD by Oct 7, 2025 to save 25%.
| | | | | |
